Treatment of multiresistant Acinetobacter baumannii infections

被引：0
|
作者：
Pachon, Jeronimo [1 ,2 ,3 ]
Vila, Jordi [3 ,4 ,5 ]
机构：
[1] Hosp Virgen Rocio, Dept Infect Dis, Seville 41013, Spain
[2] Univ Seville, Sch Med, Seville 41013, Spain
[3] Spanish Network Res Infect Dis RD06 0008, Inst Salud Carlos III, Seville 41013, Spain
[4] Hosp Clin Barcelona, Dept Clin Microbiol, E-08036 Barcelona, Spain
[5] Univ Barcelona, Sch Med, E-08036 Barcelona, Spain
来源：
CURRENT OPINION IN INVESTIGATIONAL DRUGS | 2009年 / 10卷 / 02期
关键词：
Acinetobacter baumannii; antimicrobial; enzyme inhibitor; peptide; pump inhibitor; rifampin; tigecycline; IN-VITRO ACTIVITY; MELITTIN HYBRID PEPTIDES; EFFLUX PUMP INHIBITORS; GRAM-NEGATIVE BACILLI; CECROPIN-A; ANTIMICROBIAL SUSCEPTIBILITY; TIGECYCLINE EVALUATION; MULTIDRUG-RESISTANCE; THERAPEUTIC OPTIONS; CLINICAL ISOLATE;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Acinetobacter baumannii are non-fermentative, Gram-negative bacilli that cause a large number of nosocomial infections worldwide. They are characterized by frequent multiresistance due to multiple mechanisms. As a consequence, infections caused by strains exhibiting resistance to carbapenems and, sometimes, polymyxins, are regularly observed. Sulbactam, colistin and combinations of different antimicrobials have been reported as new therapeutic approaches for infections caused by resistant A baumannii strains. This review focuses on current and potential new drugs, such as rifampin, tigecycline, antimicrobial peptides, efflux pump resistant and inhibitor drugs, and enzyme inhibitors.
引用
收藏
页码：150 / 156
页数：7
相关论文
共 50 条
  • [1] Multiresistant Acinetobacter baumannii infections: epidemiology and management
    Garnacho-Montero, Jose
    Amaya-Villar, Rosario
    CURRENT OPINION IN INFECTIOUS DISEASES, 2010, 23 (04) : 332 - 339
  • [2] Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii
    Motaouakkil, Said
    Charra, Boubaker
    Hachimi, Abdelhamid
    Nejmi, Hicham
    Benslama, Abdellatif
    Elmdaghri, Naima
    Belabbes, Habiba
    Benbachir, Mohamed
    JOURNAL OF INFECTION, 2006, 53 (04) : 274 - 278
  • [3] Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes
    Alrahmany, Diaa
    Omar, Ahmed F.
    Harb, Gehan
    El Nekidy, Wasim S.
    Ghazi, Islam M.
    ANTIBIOTICS-BASEL, 2021, 10 (06):
  • [4] Therapeutic options for infections caused by Acinetobacter baumannii
    Towner, K. J.
    ANTIBIOTIQUES, 2009, 11 (03): : 150 - 157
  • [5] Infections Due to Acinetobacter baumannii in the ICU: Treatment Options
    Lynch, Joseph P., III
    Zhanel, George G.
    Clark, Nina M.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 38 (03) : 311 - 325
  • [6] New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii
    Smani, Younes
    Eugenia Pachon-Ibanez, Maria
    Pachon, Jeronimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (09) : 1207 - 1214
  • [7] Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination
    Leclerc, T.
    Perez, J. -P.
    Debien, B.
    Clapson, P.
    Lenoir, B.
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2007, 26 (12): : 1056 - 1058
  • [8] Drug treatment for multidrug-resistant Acinetobacter baumannii infections
    Bassetti, Matteo
    Righi, Elda
    Esposito, Silvano
    Petrosillo, Nicola
    Nicolini, Laura
    FUTURE MICROBIOLOGY, 2008, 3 (06) : 649 - 660
  • [9] A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England
    Turton, JF
    Kaufmann, ME
    Warner, M
    Coelho, J
    Dijkshoorn, L
    van der Reijden, T
    Pitt, TL
    JOURNAL OF HOSPITAL INFECTION, 2004, 58 (03) : 170 - 179
  • [10] Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections
    Neshani, Alireza
    Sedighian, Hamid
    Mirhosseini, Seyed Ali
    Ghazvini, Kiarash
    Zare, Hosna
    Jahangiri, Abolfazl
    MICROBIAL PATHOGENESIS, 2020, 146
12345